Jasper Therapeutics(US:JSPR) Globenewswire·2025-09-25 22:11Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period from November 30, 2023, to July 3, 2025, alleging misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Jasper Therapeutics lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, particularly briquilimab [5]. - It is alleged that the company's public statements were materially false and misleading, leading to investor damages when the true details were revealed [5]. Group 2: Participation Information - Investors who purchased Jasper Therapeutics securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].